Dramatic changes to the regulatory landscape for in vitro diagnostic (IVD) medical devices are in the making. Some of the most impactful changes include a new classification of IVDs, an expansion of post market surveillance and the increased need for Notified Body review. Most medical device manufacturers are aware that failure to meet In Vitro Diagnostic Regulation (IVDR) 2017/746 deadlines can result in either failure to obtain a CE marking or loss of a currently valid CE mark. The deadlines, however, are not written in stone.
This article takes a closer look at the revised IVDR implementation timeline and potential impacts on certification. Access the article here.
The article is free!Simply fill in the form below, verify your email address |
Related Posts
- 54By Erica Kramer, Ph.D., Senior Nerac Analyst/Medical Writer Originally Published: June 30, 2020 In May 2017, the European Parliament and Council published Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), repealing Directive 98/79/EC (IVDD). The new regulation will apply starting May 26, 2022. Unlike under the IVDD, which allowed for self-certification for many…
- 47By Richard Conforti, M.S., Nerac Analyst, Originally Published: April 19, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In part 1…
- 47By Ron Sills, Nerac Analyst, and Donna Mitchell-Magaldi, Nerac Analyst Originally Published: September 26th, 2014 In 2009, the European Commission released MedDev 2.7.1 Rev.3 “Clinical Evaluation: A Guide for Manufacturers and Notified Bodies” as a supplement to the requirements of the EU Medical Device Directive 93/42/EEC. In order for medical devices to be marketed in…